Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CMA1 | P23946 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4220908 | 1.00 | KMT2A (0.46) | KMT2AMEN1FKBP1AF2EPHX2 | |
| SCHEMBL4229009 | 0.91 | KMT2A (0.55) | KMT2AMEN1F2EPHX2NPC1 | |
| SCHEMBL4229005 | 0.91 | KMT2A (0.55) | KMT2AMEN1F2EPHX2NPC1 | |
| SCHEMBL13878570 | 0.87 | KMT2A (0.52) | KMT2AFKBP1AF2EPHX2NPSR1 | |
| SCHEMBL13878822 | 0.87 | KMT2A (0.52) | KMT2AFKBP1AF2EPHX2NPSR1 | |
| SCHEMBL4229779 | 0.84 | FKBP1A (0.57) | KMT2AMEN1FKBP1ACMA1LMNA | |
| SCHEMBL4229783 | 0.84 | FKBP1A (0.57) | KMT2AMEN1FKBP1ACMA1LMNA | |
| SCHEMBL19984785 | 0.80 | KMT2A (0.47) | KMT2AMEN1FKBP1AF2NPC1 | |
| SCHEMBL19984786 | 0.80 | KMT2A (0.47) | KMT2AMEN1FKBP1AF2NPC1 | |
| SCHEMBL30877536 | 0.79 | KMT2A (0.47) | KMT2AMEN1FKBP1AF2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105091-A1 | Modified Amino Acids | TECHNISCHE UNIVERSITAT WIEN (AT) | 2009-04-23 | — | — | US | disclosed |
| EP-1826199-A1 | Modified amino acids | Technische Universität Wien (AT) | 2007-08-29 | — | — | EP | disclosed |
| EP-1826199-A1 | Modified amino acids | Technische Universität Wien (AT) | 2007-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105091-A1 | Modified Amino Acids | SLC1A2, NR1H4, OXGR1 | KMT2A 1541/4885MEN1 3153/4885FKBP1A 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.